Emerging insights into the role of the Hippo pathway in multiple myeloma and associated bone disease

Publication date: Available online 9 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Anastasios Kyriazoglou, Ioannis Ntanasis-Stathopoulos, Evangelos Terpos, Despina Fotiou, Efstathios Kastritis, Meletios A. Dimopoulos, Maria GavriatopoulouAbstractMultiple myeloma (MM) is an incurable plasma cell dyscrasia with numerous treatment options currently available; however, drug resistance is usually inevitable. Thus, there is a constant need for novel treatment approaches. The Hippo pathway has emerged as an important mediator of oncogenesis in solid tumors. More recently, its key role in regulating apoptosis and mediating resistance in MM and other hematologic malignancies has been demonstrated in preclinical studies, which provides a strong basis for further clinical investigation. The Hippo pathway is also implicated in the pathogenesis of MM-induced bone disease, as it regulates both osteoblast and osteoclast function. Herein, we provide an overview of the available data regarding the role of the Hippo signaling components in the pathophysiology of MM. Our better understanding of the underlying interactions at the molecular and cellular level will lead to novel and promising treatment approaches.

Source: Clinical Lymphoma Myeloma and Leukemia - October 10, 2019 Category: Cancer & Oncology Source Type: research